Roche's breast cancer hopes get a boost from postsurgery Kadcyla approval

Roche Kadcyla
Kadcyla received an FDA nod for adjutant treatment of HER-2 positive breast cancer, hopefully offsetting declining sales of Roche's Herceptin. (Roche)

As its oncology stalwart Herceptin prepares for a rush of biosimilar competitors, Roche has high hopes for another horse in the HER2-positive breast cancer space. And now, Kadcyla’s ready to run in a new indication.

Monday, the FDA approved Kadcyla for adjuvant treatment of HER-2 positive, early breast cancer patients who didn’t fully respond to drug therapy before surgery. With a new indication in hand, Kadcyla can help back up Roche’s longtime breast cancer blockbuster Herceptin, which faces biosimilar competition later this year.

Roche said the new Kadcyla nod adds an important postsurgery treatment for early breast cancer patients—and the approval came hard on the heels of new data, thanks to a new and faster FDA review pathway.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“By working closely with the FDA and participating in the Real-Time Oncology Review pilot program, we are able to make Kadcyla available for people with residual invasive disease after neoadjuvant therapy much sooner than anticipated,” Roche medical chief Sandra Horning said in a release.

The drug’s newest approval follows a round of phase 3 clinical data released in December showing “remarkable” results in treatment of breast cancer patients after Herceptin.

RELATED: Roche aims for Kadcyla expansion with new early breast cancer data

Among 1,500 patients treated with either Herceptin or Kadcyla, an "armed antibody" that contains Herceptin and chemotherapy drug DM1, those treated with Kadcyla showed an 11% improvement in fending off recurring disease or death. Jakob DuPont, Roche's former global head of breast and gynecologic cancer development, said an improvement of 2% to 3% is considered clinically promising for that measure.

Those clinical results could give Kadcyla a boost in the HER2-positive breast cancer market and eclipse its history as a sales underperformer for Roche.

Since its slower-than-expected 2013 launch, Kadcyla built up to CHF 979 million ($960 million) in 2018 sales—and that's still a fraction of the CHF 6.89 billion ($6.76 billion) Herceptin raked in during the same time period. Kadcyla showed more signs of life in the first quarter of this year with a 24% increase in global sales to CHF 291 million.

RELATED: Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help

By contrast, Roche’s other next-generation oncology drug Perjeta has seen skyrocketing sales after its pre- and postsurgery approvals for HER-2 positive breast cancer. In the first quarter alone, Perjeta cleared CHF 868 million in global sales, an impressive 41% jump.

Meanwhile, despite its continued lead as Roche’s sales blockbuster to beat, Herceptin’s performance has shown signs of cracking as biosims approach the U.S. market.

SPECIAL REPORT: Top 10 drugs losing exclusivity in 2019

Herceptin pulled in CHF 1.7 billion in global sales in the first quarter, a 6% decrease year over year. While the drug’s U.S. sales actually saw 3% growth during the same period, Roche is expected to lose ground to Herceptin’s first biosim competitor, Mylan and Biocon’s Ogivri, which is slated to launch stateside this year under a settlement with the Swiss drugmaker.

Though Roche has fought tooth and nail to keep them off the market, the FDA recently approved two more Herceptin biosimilars, Pfizer’s Trazimera and Samsung’s Bioepis, which are still tied up in litigation with Roche.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.